The U.S. Food and Drug Administration (FDA) said it is aware that Boston Scientific Corporation (NYSE: BSX) has alerted customers to remove certain AXIOS stents and electrocautery-enhanced delivery ...

Boston Scientific (NYSE:BSX) is facing multiple new securities class action lawsuits tied to disappointing earnings, lowered sales guidance, and a Class I recall of its AXIOS Stent and Delivery ...

Boston Scientific Corp BSX on Wednesday initiated the removal of certain AXIOS Stents and Electrocautery-Enhanced Delivery Systems from clinical settings following reports of deployment complications ...

FDA flags safety risk with Boston Scientific stents after reports of deployment issues causing deaths and injuries, prompting a Class I recall.

Boston Scientific is running a clinical study titled “A Prospective Multi-Center, Single-Arm Study of Endoscopic Ultrasound-Guided Gastroenterostomy With Lumen-Apposing Metal Stent for Gastric Outlet ...

Boston Scientific (NYSE:BSX) announced a Class I recall of its AXIOS Stent and Electrocautery-Enhanced Delivery Systems due ...

The RAINBOW study, officially titled “French Prospective Study on Biliary Tract Drainage Guided by Endoscopic Ultrasound in Patients With Malignant Biliary Stenosis (RAINBOW),” evaluates Boston ...